MoneyWorks4Me

Orchid Pharma Ltd (ORCHPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524372 NSE: ORCHPHARMA Pharmaceuticals & Drugs | Small Cap | Orchid Pharma Share Price

₹1,126.90 45.45 (4.20%)

As on 22-Sep'26 13:15

Orchid Pharma Ltd (ORCHPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524372 NSE: ORCHPHARMA Pharmaceuticals & Drugs | Small Cap | Orchid Pharma Share Price

₹1,126.90 45.45 (4.20%)

As on 22-Sep'26 13:15

Key Metrics
Valuation Multiples
Market Cap
₹6,476 Cr.
Current Price
₹1,126.9
52-Week Low / High
₹471 / 1,130
TTM EPS
₹1.5
TTM Sales
₹943 Cr.
Book Value per Share
₹261.7
P/E Ratio
747.32
Higher than its 5-year historical median
Industry PE
55.1
Price to Book (P/B)
4.13
Higher than its 5-year historical median
Price to Sales (P/S)
6.87
Higher than its 5-year historical median
EV/EBITDA
100.65
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
0.70%
Underperforms industry median
Return on Capital Employed (ROCE)
1.11%
Underperforms industry median
Return on Assets (ROA)
0.49%
Operating Profit Margin
1.4%
Net Profit Margin
0.86%
Gross Profit Margin
5%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-11.79%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-97.18%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-91.9%
Asset Quality
Promoter Holding
69.84%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,507 Cr.
Equity
₹59.9 Cr.
Face Value
₹10
All Time Low / High
₹3.04 / 2680.00

Orchid Pharma stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Overvalued

Price Trend

Strong
Q.1 Is Orchid Pharma Ltd a good quality company?
Orchid Pharma Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Orchid Pharma Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Orchid Pharma Ltd vs industry peers?
Orchid Pharma Ltd revenue CAGR is 22.33%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Orchid Pharma Ltd?
Promoters hold 69.84% of the Orchid Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Orchid Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 39.5% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Orchid Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % -6.4%-3.4%-3.8%-4.3%-3.5%-1.9%8.8%9%9.4%2.5%-
Value Creation
Index
NANA-1.3-1.3-1.3-1.1-0.4-0.3-0.3-0.8-

Growth Parameters

Sales 7556445844814515576668191,3981,233943
Sales YoY Gr.--14.7%-9.4%-17.6%-6.3%23.6%19.6%23.1%70.6%-11.8%-
Adj EPS -41.1-38.43.7-18.8-24.2-14.35.817.891.421.56.5
YoY Gr.-NANA-603.2%NANANA207.6%414%-76.4%-
BVPS (₹) -29.7-75.8-84.9195.5166.9166.1179.3240.21,023.71,047.2277
Adj Net
Profit
-366-34233.2-76.6-98.9-58.423.690.21403339
Cash Flow from Ops. 3185.615.280.424.489.613.413163.5142-
Debt/CF from Ops. 9.8573.5212.7718.6324.812.40.9-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 5.6%22.3%22.8%-11.8%
Adj EPS NANA55%-76.4%
BVPSNA44.4%80.1%2.3%
Share Price 40.1% 22.1% 30% 47%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
789.572.9-4.6-357.8-13.4-8.63.49.39.921
Op. Profit
Mgn %
12.26.510.6613.110.512.713.610.31.84.9
Net Profit
Mgn %
-48.4-535.7-15.9-21.9-10.53.511102.74.1
Debt to
Equity
-11.8-4.8-4.30.70.70.40.50.10.10.1-
Working Cap
Days
737735766616318271265249219325139
Cash Conv.
Cycle
6425178215114214012299145104

Valuation of Orchid Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales7976836004844505606668191,3981,233
Operating Expenses + 7096596124543995055827091,2601,229
Manufacturing Costs142116105101688697103162151
Material Costs393350290203229314385484893844
Employee Cost 8086827567636570109118
Other Costs 94106135753543355295116
Operating Profit 8724-12305155841111384
Operating Profit Margin (%) 10.9%3.6%-2.0%6.2%11.3%9.8%12.7%13.5%9.9%0.3%
Other Income + 1920172415919313966
Exceptional Items -17302010003900-7
Interest 3313107652333317139
Depreciation 1411331301181098755334243
Profit Before Tax -539-39969-70-95-57559212210
Tax -48-4600000-3-10-0
Profit After Tax -490-35369-70-95-57559513111
PAT Margin (%) -61.6%-51.7%11.6%-14.4%-21.2%-10.2%8.3%11.6%9.4%0.9%
Adjusted EPS (₹)-55.1-39.77.8-32.1-28.6-0.511.418.288.36.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + -388-792-7047666536476891,1691,5091,520
Share Capital 89898941414141511515
Reserves -477-881-7937256126076481,1191,4941,504
Debt +2,7562,5882,120504430231290134153273
Long Term Debt2,1571,8941,42550442720814912010185
Short Term Debt60069469503231411414388
Minority Interest0000000000
Trade Payables425359302102110168174230336347
Others Liabilities 5659701,359884464722079119
Total Liabilities 3,3583,1253,0771,4601,2371,1111,2251,5542,0772,258

Fixed Assets

Net Fixed Assets +1,4971,3861,256858670584573620708692
Gross Block3,0061,5191,5201,2471,1761,1761,2211,3011,4991,517
Accumulated Depreciation1,509133263389506593647681791825
CWIP 28827227826710463181414
Investments 1100154544466067
Inventories211194170142153173229264457372
Trade Receivables20312012068136171215196353381
Cash Equivalents 2573063261742083126720184
Others Assets 90184892719223512087131218248
Total Assets 3,3583,1253,0771,4601,2371,1111,2251,5542,0772,258
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 3179128124921812651126
PBT -452-39969-131-117-2468912210
Adjustment 582453571401723751444042
Changes in Working Capital 187-38-11062-3760-79-8-9571
Tax Paid 0-7-4105-2-01-152
Cash Flow From Investing Activity + -9-284516767113-31-312-36-277
Capex -9-6-7-4-0145-26-65-153-381
Net Investments -0-343714767-33-5-2599681
Others 0121524100122122
Cash Flow From Financing Activity + -36633-0-250-165-217311672137
Net Proceeds from Shares 0004000039200
Net Proceeds from Borrowing -128-10-1,044-125-205-110-220-18-23
Interest Paid -219-4-0-0-40-32-32-5-13-10
Dividend Paid 0000000000
Others -19390754020173034170
Net Cash Flow -581557-2-74-1118-1917-14
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)N/AN/AN/A-225-13.43-8.758.2710.239.790.7
ROCE (%)N/AN/AN/A-3.29-3.53-2.329.119.358.951.11
Asset Turnover Ratio0.220.210.190.210.330.480.570.590.770.57
PAT to CFO Conversion(x)N/AN/A0.17N/AN/AN/A0.331.330.3911.45
Working Capital Days
Receivable Days11685.6072.8070.9082.6099.90105.7091.5071.60108.70
Inventory Days102.40107.50110.60117.50119.50106.20110109.8094.20122.80
Payable Days370.50408.20416.60362.60169161.60162.30152.20115.60147.60

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Orchid Pharma Ltd FAQs

The current trading price of Orchid Pharma on 22-Sep-2026 13:15 is ₹1,126.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Orchid Pharma stood at ₹6,476.3 Cr

The latest P/E ratio of Orchid Pharma as of 21-Sep-2026 is 166.3.

The latest P/B ratio of Orchid Pharma as of 21-Sep-2026 is 3.90.

The 52-week high of Orchid Pharma is ₹1,130 and the 52-week low is ₹471.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Orchid Pharma is ₹943 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Orchid Pharma Ltd is a below average quality company.

The key valuation ratios of Orchid Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Orchid Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Orchid Pharma Ltd

Orchid Chemicals & Pharmaceuticals (Orchid) is pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was Incorporated in the year 1992 as a 100% export-oriented unit (EOU).

Orchid has employee strength of over 3700 people, out of which over 600 are scientists, technologists and other professionals.

The drug major has two manufacturing unit for APIs located at Alathur and Aurangabad and three facilities for fosage forms at Irungattukottai and Alathur. Besides this it two research and development centres located at Sholinganallur and Irungattukottai, Chennai.

It has formed an alliance with North China Pharmaceutical Corporation (NCPC), which is the largest pharmaceutical group in China to manufacture and market pharmaceuticals products.

The company has formed distribution and marketing alliance with various global pharmaceutical corporations including Apotex, Actavis, Hospira and Dava, among others.

Orchid owns two subsidiaries, whose core focus are on drug discovery and development namely Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. Besides this, it also has subsidiary such as Orgenus Pharma Inc (USA), Orchid Pharmaceuticals Inc (USA), Ogna Farma (South America) and Orchid Europe.

During March 2010, Orchid Chemicals & Pharmaceuticals had completed the transaction for sale and transfer of Orchid's generic injectable finished dosage forms Pharmaceuticals business to Hospira Healthcare India, a subsidiary of Hospira, Inc.

In January 2011, Orchid Chemicals & Pharmaceuticals had signed a memorandum of understanding with Great Lakes Institute of Management for setting up a centre of excellence in technopreneurship at Great Lakes campus near Chennai. The MoU was signed in the presence of APJ Abdul Kalam, former President of India, during the inauguration of Great Lakes' B-school festival, L’Attitude 13° 05’.

In April 2011, Orchid Chemicals had attained an out-of-court settlement with world's largest drug maker Pfizer Inc to sell a low-cost version of the American firm's patented anti-depressant drug, Effexor XR, (extended release) in the US market this fiscal.

In 2012
 - Orchid Pharma exit its Chinese JV with NCPC
 - Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million

In 2013
- Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics

Products

Active Pharmaceutical Ingredients- Orchid develops a wide range of APIs in category of oral cephalosporins, betalactams, special nutraceuticals, etc.

Formulations- Under this the company is engaged in developing formulation in various segment such anti-infectives, anti-oxidants, oral anti-diabetics, etc.

Awards


Orchid was awarded as the Top Indian Public Limited Company in Patent at the 5th National Intellectual Property Award 2013, organized by CII in partnership with the Department of Industrial Policy & Promotion and Indian Intellectual Property Office, Government of India.
Orchid received EXIM Achievement Award 2012 for its meritorious export performance by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ – Special Economic Zone, Government of India.

Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Hon’ble Chief Minister of Andhra Pradesh.
Orchid was awarded IGCW – 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.

Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.

In 2010, for ""Outstanding Achievement in Environment Management in the Chemical sector"", Orchid was conferred with the Silver Award by Greentech Foundation.

Orchid was awarded the ""Siemens Ecovatives-IBN Live Award 2010"" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).

In 2010, Orchid’s Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.

Orchid’s endeavour in the area of energy conservation was recognised with the “Excellent Energy Efficient Unit” in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.

Orchid’s Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune)

Orchid's Alathur facility was awarded Certificate of Appreciation by the National Safety Council of India (Safety Awards - 2011) in recognition of its appreciable achievement in Occupational Safety & Health during the assessment period of three years from 2008-10.

In 2011, Orchid received the ""Green Tech Gold Safety Award"" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India  and Mr Kamaleshwar Sharan, President, Greentech Foundation.

Orchid’s Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.

Orchid was awarded the ""Certificate of Merit Award"" for 2010 by the CII for Excellence in Environment, Health and Safety.

Orchid Research Laboratories (the discovery subsidiary of Orchid) won the Partner of Choice Award for Contract Research - Collaborative Drug Discovery by Frost & Sullivan in April 2007.

The company also bagged Gold Award for Excellence and Business Prestige was awarded at the Quality Summit 2003, New York.

 

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now